RGDX.Q Stock Overview

A life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. More details

RGDX.Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($38)

Latest financial reports are more than a year old

My Notes

Capture your thoughts, links and company narrative

Response Genetics, Inc Competitors

DermTech

OTCPK:DMTK.Q

US$35.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

MJ Holdings

OTCPK:MJNE

US$58.0

Price History & Performance

Summary of share price highs, lows and changes for Response Genetics
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-99.95%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	RGDX.Q	US Life Sciences	US Market
7D	0%	1.2%	-0.2%
1Y	n/a	-1.6%	25.8%

Return vs Industry: Insufficient data to determine how RGDX.Q performed against the US Life Sciences industry.

Return vs Market: Insufficient data to determine how RGDX.Q performed against the US Market.

Price Volatility

Is RGDX.Q's price volatile compared to industry and market?
RGDX.Q volatility
RGDX.Q Average Weekly Movement	n/a
Life Sciences Industry Average Movement	9.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: RGDX.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine RGDX.Q's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	n/a	n/a	www.responsegenetics.com

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites.

Response Genetics, Inc Fundamentals Summary

How do Response Genetics's earnings and revenue compare to its market cap?
RGDX.Q fundamental statistics
Market cap	US$38.00
Earnings (TTM)	-US$14.21m
Revenue (TTM)	US$16.62m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is RGDX.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGDX.Q income statement (TTM)
Revenue	US$16.62m
Cost of Revenue	US$10.37m
Gross Profit	US$6.25m
Other Expenses	US$20.46m
Earnings	-US$14.21m

Last Reported Earnings

Mar 31, 2015

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did RGDX.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 07:45
End of Day Share Price	2024/12/23 00:00
Earnings	2015/03/31
Annual Earnings	2014/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Response Genetics, Inc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Zarak Khurshid	Caris & Company
Kevin DeGeeter	Ladenburg Thalmann & Company
I-Eh Jen	Roth MKM